Promising cocktail aims to shrink tonsil tumors before surgery

NCT ID NCT07353723

Recruiting now Disease control Sponsor: Tang-Du Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study is testing whether a combination of two targeted drugs (nimotuzumab and toripalimab) plus standard chemotherapy can shrink locally advanced tonsillar cancer before surgery. Ten adults with resectable tumors will receive the treatment for 2-4 cycles, then have surgery. The main goal is to see if the cancer disappears completely by the time of surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nimotuzumab, toripalimab, nab-paclitaxel, and carboplatin
What this could lead to: If successful, this could point toward a more effective pre-surgery treatment for tonsillar cancer, potentially improving outcomes.
What could go wrong: This is a very small early-phase study with only 10 people, so results may not apply broadly. The drug combination may cause side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD NECK CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck cancer Head and Neck Neoplasms Pathologic Complete Response tonsillar squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEAD NECK CANCER

Contacts and locations

Locations

Tangdu Hospital, Air Force Medical University, Xi'an 710038, Shaanxi Province, China
RECRUITING

Shanxi, Province, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.